Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib for advanced or recurrent endometrial cancer after prior systemic therapy
ChiCTR2000036271Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in endometrial cancer (EC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Objective response rate and Best overall response. Started Jun 2020; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ChiCTR2000036271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036271.